Literature DB >> 15070962

Expression of urocortin III/stresscopin in human heart and kidney.

Kazuhiro Takahashi1, Kazuhito Totsune, Osamu Murakami, Masayuki Saruta, Masao Nakabayashi, Takashi Suzuki, Hironobu Sasano, Shigeki Shibahara.   

Abstract

Urocortin III (Ucn III)/stresscopin (SCP) is a novel peptide of the corticotropin-releasing factor (CRF) family and is a specific ligand for the CRF type 2 receptor. We wished to clarify whether Ucn III/SCP is expressed in the human heart and kidney. Immunoreactive Ucn III was detected by RIA in the human heart (0.74-1.15 pmol/g wet weight, mean +/- SEM; n = 4) and kidney (1.21 +/- 0.30 pmol/g wet weight), which were obtained at autopsy. These levels were comparable to the levels in pituitary (2.72 +/- 0.13 pmol/g wet weight; n = 3) and brain tissues ( approximately 1-2 pmol/g wet weight). Furthermore, immunoreactive Ucn III was present in human plasma (51.8 +/- 16.0 pmol/liter; n = 5) and urine (266 +/- 20 pmol/liter; n = 5) obtained from healthy subjects. Reverse-phase HPLC showed a broad peak of immunoreactive Ucn III eluting in the position of synthetic Ucn III in the heart, kidney, and hypothalamus. Material eluting in the position of SCP was also found in the HPLC analysis of these tissue extracts. Immunocytochemistry showed positive staining of Ucn III in the myocardium and the renal tubules, particularly distal tubules. RT-PCR showed expression of Ucn III mRNA in the brain, pituitary, heart, and kidney. The present study has shown expression of Ucn III/SCP in the human heart and kidney as well as brain and pituitary tissues and its presence in plasma and urine. Ucn III/SCP may therefore regulate the cardiac and renal function as a local factor and a circulating hormone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15070962     DOI: 10.1210/jc.2003-031663

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

1.  Type 2 corticotropin-releasing factor receptor in the ventromedial nucleus of hypothalamus is critical in regulating feeding and lipid metabolism in white adipose tissue.

Authors:  Hongxia Chao; Michael Digruccio; Peilin Chen; Chien Li
Journal:  Endocrinology       Date:  2011-11-08       Impact factor: 4.736

2.  Presence of kisspeptin-like immunoreactivity in human adrenal glands and adrenal tumors.

Authors:  Kazuhiro Takahashi; Itaru Shoji; Akiko Shibasaki; Ichiro Kato; Keisuke Hiraishi; Hajime Yamamoto; Kiriko Kaneko; Osamu Murakami; Ryo Morimoto; Fumitoshi Satoh; Sadayoshi Ito; Kazuhito Totsune
Journal:  J Mol Neurosci       Date:  2009-11-07       Impact factor: 3.444

Review 3.  The corticotropin releasing factor system in cancer: expression and pathophysiological implications.

Authors:  Athina Kaprara; Kalliopi Pazaitou-Panayiotou; Alexandros Kortsaris; Ekaterini Chatzaki
Journal:  Cell Mol Life Sci       Date:  2010-02-09       Impact factor: 9.261

4.  Expression of urocortin peptides in canine myocardium and plasma.

Authors:  Gemma Fraga Veloso; Dan G Ohad; Andrew J Francis; Joan M Vaughan; David G Brownstein; Geoffrey J Culshaw; Wylie W Vale; Anne T French; Pauline M Jamieson
Journal:  Vet J       Date:  2010-06-15       Impact factor: 2.688

Review 5.  Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs.

Authors:  Eva M Fekete; Eric P Zorrilla
Journal:  Front Neuroendocrinol       Date:  2006-11-02       Impact factor: 8.606

6.  Cardiac CRFR1 Expression Is Elevated in Human Heart Failure and Modulated by Genetic Variation and Alternative Splicing.

Authors:  Anna P Pilbrow; Kathy A Lewis; Marilyn H Perrin; Wendy E Sweet; Christine S Moravec; W H Wilson Tang; Mark O Huising; Richard W Troughton; Vicky A Cameron
Journal:  Endocrinology       Date:  2016-10-18       Impact factor: 4.736

7.  Urocortin 3 expression at baseline and during inflammation in the colon: corticotropin releasing factor receptors cross-talk.

Authors:  Shilpi Mahajan; Min Liao; Paris Barkan; Kazuhiro Takahashi; Aditi Bhargava
Journal:  Peptides       Date:  2014-01-22       Impact factor: 3.750

8.  Cardiovascular responses to microinjections of urocortin 3 into the nucleus tractus solitarius of the rat.

Authors:  Takeshi Nakamura; Kazumi Kawabe; Hreday N Sapru
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-12-05       Impact factor: 4.733

9.  Regulation and roles of urocortins in the vascular system.

Authors:  Kazunori Kageyama; Ken Teui; Naoki Tamasawa; Toshihiro Suda
Journal:  Int J Endocrinol       Date:  2012-05-13       Impact factor: 3.257

10.  Clinical perspectives of urocortin and related agents for the treatment of cardiovascular disease.

Authors:  Keiichi Ikeda; Kouki Fujioka; Yoshinobu Manome; Katsuyoshi Tojo
Journal:  Int J Endocrinol       Date:  2012-04-03       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.